SMYD3 and small cell lung carcinoma: To further validate the SMYD3 role in mitigating alkylating chemotherapy efficacy, we tested a panel of SCLC cell lines (H209, H1092, and DMS-114) using the SMYD3 inhibitor EPZ031686 (SMYD3i) and two established alkylating drugs, 4H-CP and methyl methanesulfonate (MMS; Supplementary Fig. S1C–S1H).